Hypertensive disorders of pregnancy may increase the risk of neurodevelopmental delay in the offspring: a systematic review with meta-analysis.

Hypertens ResAug 3, 2026 (epub)
Clinical ResearchObstetrics & GynecologyPediatricsOpen access

Leslie Marilu Zavala-Martínez, Erika Marlen Hurtado-Salgado, Mary Carmen Baltazar-Reyes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of hypertensive disorders of pregnancy (HDP) on neurodevelopmental delay in offspring. Analyzing data from 21 studies, it found that children exposed to HDP had a doubled risk of global neurodevelopmental delay (OR = 2.07; 95% CI: 1.08, 3.95) compared to unexposed children.

Key findings

  • Children exposed to HDP had a 2.07 odds ratio for global neurodevelopmental delay.
  • The risk of delayed motor development was increased with an odds ratio of 1.25.
  • Language development delay was associated with an odds ratio of 1.87 in exposed children.
  • Cognitive development delay showed an odds ratio of 1.27, though not statistically significant.

Why it matters

Understanding the association between hypertensive disorders of pregnancy and neurodevelopmental outcomes is crucial for clinicians. It highlights the need for monitoring and potential early interventions for children at risk due to maternal health complications.

Source

PubMed · PMID 42547561Free full text on PubMed Central

Published in Hypertens Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.